NCT00688948View on ClinicalTrials.gov

Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Multiple SclerosisBladder Dysfunction
Interventions
DRUG

Alfuzosin

Alfuzosin 10 mg once daily po for 12 weeks

Trial Locations (1)

B3H 3A7

QE II Health Science Centre, Halifax Infirmary, Halifax

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Nova Scotia Health Authority

OTHER